Heterotopic caval valve implantation in severe tricuspid regurgitation

Severe symptomatic tricuspid regurgitation (TR) with right heart failure is associated with significant morbidity and mortality. Medical therapy is often ineffective and surgical correction is not feasible due to prohibitive perioperative risk. Transcatheter caval valve implantation (CAVI) is an evolving therapeutic option for this condition. It refers to the heterotopic placement of a valve into the inferior vena cava alone or with a second valve in the superior vena cava to restrict the backflow from the failing tricuspid valve. We hereby describe a patient with previous mitral valve surgery with chronic severe TR who underwent successful CAVI at our institute.

Automated summary

Patients with severe symptomatic tricuspid regurgitation (TR) often experience high morbidity and mortality rates. Transcatheter caval valve implantation (CAVI) is emerging as an effective therapeutic option for restricting TR backflow, especially in cases where surgical correction is not feasible.